NASTRAN general purpose interface requirements document

This NASTRAN (NASA STRuctural ANalysis) General Purpose Interface Requirements Document (IRD) defines standards for deliverables required of New Capability Contractors (NCCs) and relates these deliverables to the software development cycle. It also defines standards to be followed by NCCs for adding to and modifying the code in the NASTRAN software system and for adding to and modifying the four official NASTRAN manuals: The NASTRAN Theoretical Manual, the NASTRAN User's Manual, The NASTRAN Programmer's Manual, and The NASTRAN Demonstration Problem Manual. It is intended that this General Purpose IRD shall be incorporated by reference in all contracts for a new NASTRAN capability

Studies of new antiferroelectric liquid crystal based on quantum-chemical model

Physical properties of new thermotropic antiferroelectric liquid crystal have been studied. Experiments were done by use of complementary methods such as differential scanning calorimetry, polarizing optical microscopy and X-ray powder diffractometry. Acquired data from X-ray powder diffractometry was examined under application of quantum chemical approach. It has been found that compound studied exhibits stable enantiotropic antiferroelectric SmC_{A}^{*} phase in the wide temperature range while ferroelectric phase SmC^{*} is very narrow

Thin-Film CIGS Photovoltaic Technology; Annual Technical Report, Phase I; 16 April 1998 - 15 April 1999

This report describes work performed by Energy Photovoltaics, Inc. (EPV) under Phase I of this subcontract. EPV's new FORNAX process for CIGS formation is capable of producing devices with high V{sub oc} (>600 mV) and no dark aging effects. Parameters of the best device so far are V{sub oc} = 611 mV, J{sub sc} = 27.5 mA/cm{sup 2}, FF = 74.5%, and efficiency = 12.5%. A 34-cm{sup 2} 16-cell minimodule was produced using FORNAX CIGS with V{sub oc} = 9.58 V, I{sub sc} = 52.0 mA, FF = 69.8%, and efficiency = 10.2%. A new version of EPV's linear evaporation source was developed with improved rate and uniformity for Cu deposition over a width of 45 cm. Using the new linear source, the FORNAX process was implemented on 0.43-m{sub 2} substrates in EPV's CIGS pilot line, with V{sub oc} = 537 mV and FF = 70.3% being achieved on a device. The EPV Subteam of the National CIS R&D Team has produced Cd-free ZnO/CIGS devices on NREL CIGS using the ROMEAO process (reaction of metal and atomic oxygen) for ZnO deposition. After soaking, the best device exhibited a V{sub oc} of 565 mV and an efficiency of 12.3%. Novel bias drive methods were devised for field soaking/anti-soaking experiments as a function of time and temperature. Scaling laws and an activation energy of 0.51 eV were found. Thermally stimulated capacitance reveals the existence of three distinct contributions to ZnO/CIGS device capacitance, two appearing to be gap-state effects and one related to net doping concentration. The coating time of the sputtered pilot-line ZnO:Al has been reduced by a factor of 3 while maintaining film quality. The deposition rate is 48 A s{sup -1}. Plans are under way to increase the substrate size from 0.43 m{sup 2} to 0.79 m{sup 2}

Scn8a Antisense Oligonucleotide Is Protective in Mouse Models of SCN8A Encephalopathy and Dravet Syndrome

Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/154348/1/ana25676.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/154348/2/ana25676_am.pd

Engineered liposomes sequester bacterial exotoxins and protect from severe invasive infections in mice

Gram-positive bacterial pathogens that secrete cytotoxic pore-forming toxins, such as Staphylococcus aureus and Streptococcus pneumoniae, cause a substantial burden of disease. Inspired by the principles that govern natural toxin-host interactions, we have engineered artificial liposomes that are tailored to effectively compete with host cells for toxin binding. Liposome-bound toxins are unable to lyse mammalian cells in vitro. We use these artificial liposomes as decoy targets to sequester bacterial toxins that are produced during active infection in vivo. Administration of artificial liposomes within 10 h after infection rescues mice from septicemia caused by S. aureus and S. pneumoniae, whereas untreated mice die within 24-33 h. Furthermore, liposomes protect mice against invasive pneumococcal pneumonia. Composed exclusively of naturally occurring lipids, tailored liposomes are not bactericidal and could be used therapeutically either alone or in conjunction with antibiotics to combat bacterial infections and to minimize toxin-induced tissue damage that occurs during bacterial clearance

Frequency of and factors associated with antiseizure medication discontinuation discussions and decisions in patients with epilepsy: a multicenter retrospective chart review

Objective: Guidelines suggest considering antiseizure medication (ASM) discontinuation in patients with epilepsy who become seizure-free. Little is known about how discontinuation decisions are being made in practice. We measured the frequency of, and factors associated with, discussions and decisions surrounding ASM discontinuation. Methods: We performed a multicenter retrospective cohort study at the University of Michigan (UM) and two Dutch centers: Wilhelmina Children's Hospital (WCH) and Stichting Epilepsie Instellingen Nederland (SEIN). We screened all children and adults with outpatient epilepsy visits in January 2015 and included those with at least one visit during the subsequent 2 years where they were seizure-free for at least one year. We recorded whether charts documented (1) a discussion with the patient about possible ASM discontinuation and (2) any planned attempt to discontinue at least one ASM. We conducted multilevel logistic regressions to determine factors associated with each outcome. Results: We included 1058 visits from 463 patients. Of all patients who were seizure-free at least one year, 248/463 (53%) had documentation of any discussion and 98/463 (21%) planned to discontinue at least one ASM. Corresponding frequencies for patients who were seizure-free at least 2 years were 184/285 (65%) and 74/285 (26%). The probability of discussing or discontinuing increased with longer duration of seizure freedom. Still, even for patients who were 10 years seizure-free, our models predicated that in only 49% of visits was a discontinuation discussion documented, and in only 16% of visits was it decided to discontinue all ASMs. Provider-to-provider variation explained 18% of variation in whether patients discontinued any ASM. Significance: Only approximately half of patients with prolonged seizure freedom had a documented discussion about ASM discontinuation. Discontinuation was fairly rare even among low-risk patients. Future work should further explore barriers to and facilitators of counseling and discontinuation attempts

Variation in seizure risk increases from antiseizure medication withdrawal among patients with well-controlled epilepsy: a pooled analysis

Objective: Guidelines suggest considering antiseizure medication (ASM) discontinuation in seizure-free patients with epilepsy. Past work has poorly explored how discontinuation effects vary between patients. We evaluated (1) what factors modify the influence of discontinuation on seizure risk; and (2) the range of seizure risk increase due to discontinuation across low- versus high-risk patients. Methods: We pooled three datasets including seizure-free patients who did and did not discontinue ASMs. We conducted time-to-first-seizure analyses. First, we evaluated what individual patient factors modified the relative effect of ASM discontinuation on seizure risk via interaction terms. Then, we assessed the distribution of 2-year risk increase as predicted by our adjusted logistic regressions. Results: We included 1626 patients, of whom 678 (42%) planned to discontinue all ASMs. The mean predicted 2-year seizure risk was 43% [95% confidence interval (CI) 39%–46%] for discontinuation versus 21% (95% CI 19%–24%) for continuation. The mean 2-year absolute seizure risk increase was 21% (95% CI 18%–26%). No individual interaction term was significant after correcting for multiple comparisons. The median [interquartile range (IQR)] risk increase across patients was 19% (IQR 14%–24%; range 7%–37%). Results were unchanged when restricting analyses to only the two RCTs. Significance: No single patient factor significantly modified the influence of discontinuation on seizure risk, although we captured how absolute risk increases change for patients that are at low versus high risk. Patients should likely continue ASMs if even a 7% 2-year increase in the chance of any more seizures would be too much and should likely discontinue ASMs if even a 37% risk increase would be too little. In between these extremes, individualized risk calculation and a careful understanding of patient preferences are critical. Future work will further develop a two-armed individualized seizure risk calculator and contextualize seizure risk thresholds below which to consider discontinuation. Plain Language Summary: Understanding how much antiseizure medications (ASMs) decrease seizure risk is an important part of determining which patients with epilepsy should be treated, especially for patients who have not had a seizure in a while. We found that there was a wide range in the amount that ASM discontinuation increases seizure risk—between 7% and 37%. We found that no single patient factor modified that amount. Understanding what a patient's seizure risk might be if they discontinued versus continued ASM treatment is critical to making informed decisions about whether the benefit of treatment outweighs the downsides

Total antioxidant activity and trace elements in human milk: the first 4 months of breast-feeding

The content of many nutrients in breast milk are dependent on the nutritional status of the lactating woman. This is particularly true for fat and water-soluble vitamins, some of which have antioxidant properties. The aim of the study entertained herein was to evaluate the changes in total antioxidant status of human milk during the first 4 months of lactation, and to correlate such changes with the contents in specific antioxidant oligoelements (Cu, Zn, Mn and Se). Milk samples were collected from (31) lactating women recruited at the Service of Obstetrics of the Hospital de São João in Porto, after 1, 4, 8, 12 and 16 weeks after birth. The total antioxidant status (TAS) of human milk was measured by the Randox® commercial kit and trace metals by ICP-MS (inductively coupled plasma-mass spectrometry). The results found for TAS and oligoelements under study show a decrease in the concentration of these parameters from 7 days to 4 months of breast-feeding and significant correlations (p < 0.05) were found between TAS and Cu, Zn and Se (not Mn). The decreases of Cu, Zn and Se were also correlated, but not proportional between them, suggesting diverse excretion mechanisms for all. Between primipara and multipara women, a significant difference was found only for Cu and Zn concentrations at 7 days of lactation, but not for the other metals or TAS. With respect to the mother’s age, no correlation was found, either for trace metal concentrations or TAS

Site-Specific and Time-Dependent Activation of the Endocannabinoid System after Transection of Long-Range Projections

Background: After focal neuronal injury the endocannabinioid system becomes activated and protects or harms neurons depending on cannabinoid derivates and receptor subtypes. Endocannabinoids (eCBs) play a central role in controlling local responses and influencing neural plasticity and survival. However, little is known about the functional relevance of eCBs in long-range projection damage as observed in stroke or spinal cord injury (SCI). Methods: In rat organotypic entorhino-hippocampal slice cultures (OHSC) as a relevant and suitable model for investigating projection fibers in the CNS we performed perforant pathway transection (PPT) and subsequently analyzed the spatial and temporal dynamics of eCB levels. This approach allows proper distinction of responses in originating neurons (entorhinal cortex), areas of deafferentiation/anterograde axonal degeneration (dentate gyrus) and putative changes in more distant but synaptically connected subfields (cornu ammonis (CA) 1 region). Results: Using LC-MS/MS, we measured a strong increase in arachidonoylethanolamide (AEA), oleoylethanolamide (OEA) and palmitoylethanolamide (PEA) levels in the denervation zone (dentate gyrus) 24 hours post lesion (hpl), whereas entorhinal cortex and CA1 region exhibited little if any changes. NAPE-PLD, responsible for biosynthesis of eCBs, was increased early, whereas FAAH, a catabolizing enzyme, was up-regulated 48hpl. Conclusion: Neuronal damage as assessed by transection of long-range projections apparently provides a strong time-dependent and area-confined signal for de novo synthesis of eCB, presumably to restrict neuronal damage. The present data underlines the importance of activation of the eCB system in CNS pathologies and identifies a novel site-specific intrinsic regulation of eCBs after long-range projection damage